Anzeige
Mehr »
Samstag, 25.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40LEL | ISIN: US00439U1043 | Ticker-Symbol: L8S
NASDAQ
24.10.25 | 21:59
3,150 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
GRACE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GRACE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur GRACE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoGrace Therapeutics secures $4M through common warrant exercises4
DoGrace Therapeutics sichert sich 4 Millionen US-Dollar durch Ausübung von Optionsscheinen2
DoGrace Therapeutics, Inc. - 8-K, Current Report1
18.09.Grace Therapeutics receives patent for nimodipine IV dosing regimen2
18.09.Grace Therapeutics sichert Patentschutz für Nimodipin-Präparat bis 20433
GRACE THERAPEUTICS Aktie jetzt für 0€ handeln
18.09.Grace Therapeutics, Inc.: Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104198Grant of First Method of Use Patent Adds New Pillar to Grace's Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept....
► Artikel lesen
12.09.Grace Therapeutics, Inc. - 8-K, Current Report1
27.08.Grace Therapeutics: FDA To Review NDA For GTx-1042
27.08.Grace Therapeutics, Inc. - 8-K, Current Report2
27.08.Grace Therapeutics, Inc.: Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104311FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive...
► Artikel lesen
12.08.Grace Therapeutics GAAP EPS of -$0.21 beats by $0.012
12.08.Grace Therapeutics, Inc.: Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update187Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)...
► Artikel lesen
12.08.Grace Therapeutics, Inc. - 8-K, Current Report1
12.08.Grace Therapeutics, Inc. - 10-Q, Quarterly Report1
25.06.Grace Therapeutics, Inc.: Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104300Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety...
► Artikel lesen
23.06.Grace Therapeutics GAAP EPS of -$0.791
23.06.Grace Therapeutics, Inc. - 8-K, Current Report1
23.06.Grace Therapeutics, Inc. - 10-K, Annual Report2
02.05.TD Cowen starts Grace Therapeutics stock with Buy, $12 target3
09.04.Grace Therapeutics, Inc.: Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104566PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1